Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis

[Display omitted] Isoniazid-naphthoquinone hybrids were synthesized and evaluated against a susceptible (H37Rv) strain and two isoniazid-resistant strains (INHR1 and INHR2) of Mycobacterium tuberculosis. The antimycobacterial activity of the derivatives was determined based on the resazurin microtit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry 2019-09, Vol.27 (18), p.4143-4150
Hauptverfasser: Reis, Wallace J., Bozzi, Ícaro A.O., Ribeiro, Matheus F., Halicki, Priscila C.B., Ferreira, Laís A., Almeida da Silva, Pedro E., Ramos, Daniela F., de Simone, Carlos A., da Silva Júnior, Eufrânio N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4150
container_issue 18
container_start_page 4143
container_title Bioorganic & medicinal chemistry
container_volume 27
creator Reis, Wallace J.
Bozzi, Ícaro A.O.
Ribeiro, Matheus F.
Halicki, Priscila C.B.
Ferreira, Laís A.
Almeida da Silva, Pedro E.
Ramos, Daniela F.
de Simone, Carlos A.
da Silva Júnior, Eufrânio N.
description [Display omitted] Isoniazid-naphthoquinone hybrids were synthesized and evaluated against a susceptible (H37Rv) strain and two isoniazid-resistant strains (INHR1 and INHR2) of Mycobacterium tuberculosis. The antimycobacterial activity of the derivatives was determined based on the resazurin microtiter assay and their cytotoxicity in adhered mouse monocyte macrophage J774.A1 cells (ATCC TIB-67). Of the twenty-two compounds evaluated against the three strains of M. tuberculosis, twenty-one presented some activity against the H37Rv and INHR1 (katG S315T) or INHR2 (inhA C(−5)T) strains. Compounds 1a, 2a, and 8a were effective against the INHR1 strain, and compounds 1a, 1b, 2a, 3a, 5a, 5b and 8a were effective against the INHR2 strain, with MICs in the range of 3.12–6.25 µg/mL. Compounds 1b and 5b were the most active against H37Rv, with MIC of 0.78 µg/mL. Based on the selectivity index, 1b and 5b can be considered safe as a drug candidate compounds. These results demonstrate that quinoidal compounds can be used as promising scaffolds for the development of new anti-TB drugs and hybrids with activity against M. tuberculosis-susceptible and INH-resistant strains.
doi_str_mv 10.1016/j.bmc.2019.07.045
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2268573676</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089619306418</els_id><sourcerecordid>2268573676</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-91236112d1a4eade15399eb90faa579cfbfb79ec5aae922517c2ba6112d041203</originalsourceid><addsrcrecordid>eNp9kcuO1DAQRS0EYpqBD2CDvGSTYDuvNqzQDC9pEAtgbdlOZbpaiR1sp6Xwg_wWzvQAOyRL3pxzq0qXkOeclZzx9tWxNJMtBeOyZF3J6uYB2fG6rYuqkvwh2THZ7gu2l-0FeRLjkTEmaskfk4uKV92-kc2O_LqGiLeO-oEeVhOwp5MfwS4jRKrzcwmn1XqjbYKAeqTWT7NfXB9f06-rS4esx83G6B3qn9gXTs-HdPA_FnTeAe2zd9IJT1ui62lWMNCchydMK9W3Gl1MNC7RwpzQjHCHhS045fk0prAh25DP_1ZZJpoWAyGv6jP5lDwa9Bjh2f1_Sb6_f_ft6mNx8-XDp6u3N4WtZJsKyUXVci56rmvQPfCmkhKMZIPWTSftYAbTSbCN1iCFaHhnhdF3Bqu5YNUleXnOnUO-EGJSE-bFx1E78EtUQrT7pqvars0oP6M2-BgDDGoOOOmwKs7U1p86qtyf2vpTrFO5v-y8uI9fzAT9X-NPYRl4cwYgH3lCCCpaBGehxwA2qd7jf-J_A2G6svQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2268573676</pqid></control><display><type>article</type><title>Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Reis, Wallace J. ; Bozzi, Ícaro A.O. ; Ribeiro, Matheus F. ; Halicki, Priscila C.B. ; Ferreira, Laís A. ; Almeida da Silva, Pedro E. ; Ramos, Daniela F. ; de Simone, Carlos A. ; da Silva Júnior, Eufrânio N.</creator><creatorcontrib>Reis, Wallace J. ; Bozzi, Ícaro A.O. ; Ribeiro, Matheus F. ; Halicki, Priscila C.B. ; Ferreira, Laís A. ; Almeida da Silva, Pedro E. ; Ramos, Daniela F. ; de Simone, Carlos A. ; da Silva Júnior, Eufrânio N.</creatorcontrib><description>[Display omitted] Isoniazid-naphthoquinone hybrids were synthesized and evaluated against a susceptible (H37Rv) strain and two isoniazid-resistant strains (INHR1 and INHR2) of Mycobacterium tuberculosis. The antimycobacterial activity of the derivatives was determined based on the resazurin microtiter assay and their cytotoxicity in adhered mouse monocyte macrophage J774.A1 cells (ATCC TIB-67). Of the twenty-two compounds evaluated against the three strains of M. tuberculosis, twenty-one presented some activity against the H37Rv and INHR1 (katG S315T) or INHR2 (inhA C(−5)T) strains. Compounds 1a, 2a, and 8a were effective against the INHR1 strain, and compounds 1a, 1b, 2a, 3a, 5a, 5b and 8a were effective against the INHR2 strain, with MICs in the range of 3.12–6.25 µg/mL. Compounds 1b and 5b were the most active against H37Rv, with MIC of 0.78 µg/mL. Based on the selectivity index, 1b and 5b can be considered safe as a drug candidate compounds. These results demonstrate that quinoidal compounds can be used as promising scaffolds for the development of new anti-TB drugs and hybrids with activity against M. tuberculosis-susceptible and INH-resistant strains.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/j.bmc.2019.07.045</identifier><identifier>PMID: 31378595</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antimycobacterial compounds ; Hybrid molecules ; Isoniazid-naphthoquinone derivatives ; Mycobacterium tuberculosis ; Quinone ; Tuberculosis</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2019-09, Vol.27 (18), p.4143-4150</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-91236112d1a4eade15399eb90faa579cfbfb79ec5aae922517c2ba6112d041203</citedby><cites>FETCH-LOGICAL-c396t-91236112d1a4eade15399eb90faa579cfbfb79ec5aae922517c2ba6112d041203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bmc.2019.07.045$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31378595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reis, Wallace J.</creatorcontrib><creatorcontrib>Bozzi, Ícaro A.O.</creatorcontrib><creatorcontrib>Ribeiro, Matheus F.</creatorcontrib><creatorcontrib>Halicki, Priscila C.B.</creatorcontrib><creatorcontrib>Ferreira, Laís A.</creatorcontrib><creatorcontrib>Almeida da Silva, Pedro E.</creatorcontrib><creatorcontrib>Ramos, Daniela F.</creatorcontrib><creatorcontrib>de Simone, Carlos A.</creatorcontrib><creatorcontrib>da Silva Júnior, Eufrânio N.</creatorcontrib><title>Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>[Display omitted] Isoniazid-naphthoquinone hybrids were synthesized and evaluated against a susceptible (H37Rv) strain and two isoniazid-resistant strains (INHR1 and INHR2) of Mycobacterium tuberculosis. The antimycobacterial activity of the derivatives was determined based on the resazurin microtiter assay and their cytotoxicity in adhered mouse monocyte macrophage J774.A1 cells (ATCC TIB-67). Of the twenty-two compounds evaluated against the three strains of M. tuberculosis, twenty-one presented some activity against the H37Rv and INHR1 (katG S315T) or INHR2 (inhA C(−5)T) strains. Compounds 1a, 2a, and 8a were effective against the INHR1 strain, and compounds 1a, 1b, 2a, 3a, 5a, 5b and 8a were effective against the INHR2 strain, with MICs in the range of 3.12–6.25 µg/mL. Compounds 1b and 5b were the most active against H37Rv, with MIC of 0.78 µg/mL. Based on the selectivity index, 1b and 5b can be considered safe as a drug candidate compounds. These results demonstrate that quinoidal compounds can be used as promising scaffolds for the development of new anti-TB drugs and hybrids with activity against M. tuberculosis-susceptible and INH-resistant strains.</description><subject>Antimycobacterial compounds</subject><subject>Hybrid molecules</subject><subject>Isoniazid-naphthoquinone derivatives</subject><subject>Mycobacterium tuberculosis</subject><subject>Quinone</subject><subject>Tuberculosis</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kcuO1DAQRS0EYpqBD2CDvGSTYDuvNqzQDC9pEAtgbdlOZbpaiR1sp6Xwg_wWzvQAOyRL3pxzq0qXkOeclZzx9tWxNJMtBeOyZF3J6uYB2fG6rYuqkvwh2THZ7gu2l-0FeRLjkTEmaskfk4uKV92-kc2O_LqGiLeO-oEeVhOwp5MfwS4jRKrzcwmn1XqjbYKAeqTWT7NfXB9f06-rS4esx83G6B3qn9gXTs-HdPA_FnTeAe2zd9IJT1ui62lWMNCchydMK9W3Gl1MNC7RwpzQjHCHhS045fk0prAh25DP_1ZZJpoWAyGv6jP5lDwa9Bjh2f1_Sb6_f_ft6mNx8-XDp6u3N4WtZJsKyUXVci56rmvQPfCmkhKMZIPWTSftYAbTSbCN1iCFaHhnhdF3Bqu5YNUleXnOnUO-EGJSE-bFx1E78EtUQrT7pqvars0oP6M2-BgDDGoOOOmwKs7U1p86qtyf2vpTrFO5v-y8uI9fzAT9X-NPYRl4cwYgH3lCCCpaBGehxwA2qd7jf-J_A2G6svQ</recordid><startdate>20190915</startdate><enddate>20190915</enddate><creator>Reis, Wallace J.</creator><creator>Bozzi, Ícaro A.O.</creator><creator>Ribeiro, Matheus F.</creator><creator>Halicki, Priscila C.B.</creator><creator>Ferreira, Laís A.</creator><creator>Almeida da Silva, Pedro E.</creator><creator>Ramos, Daniela F.</creator><creator>de Simone, Carlos A.</creator><creator>da Silva Júnior, Eufrânio N.</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190915</creationdate><title>Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis</title><author>Reis, Wallace J. ; Bozzi, Ícaro A.O. ; Ribeiro, Matheus F. ; Halicki, Priscila C.B. ; Ferreira, Laís A. ; Almeida da Silva, Pedro E. ; Ramos, Daniela F. ; de Simone, Carlos A. ; da Silva Júnior, Eufrânio N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-91236112d1a4eade15399eb90faa579cfbfb79ec5aae922517c2ba6112d041203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antimycobacterial compounds</topic><topic>Hybrid molecules</topic><topic>Isoniazid-naphthoquinone derivatives</topic><topic>Mycobacterium tuberculosis</topic><topic>Quinone</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reis, Wallace J.</creatorcontrib><creatorcontrib>Bozzi, Ícaro A.O.</creatorcontrib><creatorcontrib>Ribeiro, Matheus F.</creatorcontrib><creatorcontrib>Halicki, Priscila C.B.</creatorcontrib><creatorcontrib>Ferreira, Laís A.</creatorcontrib><creatorcontrib>Almeida da Silva, Pedro E.</creatorcontrib><creatorcontrib>Ramos, Daniela F.</creatorcontrib><creatorcontrib>de Simone, Carlos A.</creatorcontrib><creatorcontrib>da Silva Júnior, Eufrânio N.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reis, Wallace J.</au><au>Bozzi, Ícaro A.O.</au><au>Ribeiro, Matheus F.</au><au>Halicki, Priscila C.B.</au><au>Ferreira, Laís A.</au><au>Almeida da Silva, Pedro E.</au><au>Ramos, Daniela F.</au><au>de Simone, Carlos A.</au><au>da Silva Júnior, Eufrânio N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2019-09-15</date><risdate>2019</risdate><volume>27</volume><issue>18</issue><spage>4143</spage><epage>4150</epage><pages>4143-4150</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>[Display omitted] Isoniazid-naphthoquinone hybrids were synthesized and evaluated against a susceptible (H37Rv) strain and two isoniazid-resistant strains (INHR1 and INHR2) of Mycobacterium tuberculosis. The antimycobacterial activity of the derivatives was determined based on the resazurin microtiter assay and their cytotoxicity in adhered mouse monocyte macrophage J774.A1 cells (ATCC TIB-67). Of the twenty-two compounds evaluated against the three strains of M. tuberculosis, twenty-one presented some activity against the H37Rv and INHR1 (katG S315T) or INHR2 (inhA C(−5)T) strains. Compounds 1a, 2a, and 8a were effective against the INHR1 strain, and compounds 1a, 1b, 2a, 3a, 5a, 5b and 8a were effective against the INHR2 strain, with MICs in the range of 3.12–6.25 µg/mL. Compounds 1b and 5b were the most active against H37Rv, with MIC of 0.78 µg/mL. Based on the selectivity index, 1b and 5b can be considered safe as a drug candidate compounds. These results demonstrate that quinoidal compounds can be used as promising scaffolds for the development of new anti-TB drugs and hybrids with activity against M. tuberculosis-susceptible and INH-resistant strains.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31378595</pmid><doi>10.1016/j.bmc.2019.07.045</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2019-09, Vol.27 (18), p.4143-4150
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_2268573676
source ScienceDirect Journals (5 years ago - present)
subjects Antimycobacterial compounds
Hybrid molecules
Isoniazid-naphthoquinone derivatives
Mycobacterium tuberculosis
Quinone
Tuberculosis
title Design of hybrid molecules as antimycobacterial compounds: Synthesis of isoniazid-naphthoquinone derivatives and their activity against susceptible and resistant strains of Mycobacterium tuberculosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T00%3A19%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20of%20hybrid%20molecules%20as%20antimycobacterial%20compounds:%20Synthesis%20of%20isoniazid-naphthoquinone%20derivatives%20and%20their%20activity%20against%20susceptible%20and%20resistant%20strains%20of%20Mycobacterium%20tuberculosis&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Reis,%20Wallace%20J.&rft.date=2019-09-15&rft.volume=27&rft.issue=18&rft.spage=4143&rft.epage=4150&rft.pages=4143-4150&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/j.bmc.2019.07.045&rft_dat=%3Cproquest_cross%3E2268573676%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2268573676&rft_id=info:pmid/31378595&rft_els_id=S0968089619306418&rfr_iscdi=true